EMA Authorised: Janumet (sitagliptin;metformin hydrochloride) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA has authorised Janumet (sitagliptin and metformin) for the treatment of type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Janumet (sitagliptin/metformin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Merck Sharp & Dohme B.V.. Decision date: 10/11/2025